新辅助纳武利尤单抗联合铂类化疗后可切除非小细胞肺癌手术结果:欧洲多中心真实世界分析
OBJECTIVES: To evaluate the real clinical practice surgical outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre European cohort of patients.…
要点
- 病理完全缓解率30%,主要病理缓解率52.7%,鳞癌缓解率高于非鳞癌。
核心结论
- 真实临床实践中新辅助纳武利尤单抗联合铂类化疗用于可切除II-IIIB期非小细胞肺癌安全有效。
主要发现
- 95例(占手术患者30%)达病理完全缓解,167例(52.7%)达主要病理缓解。
- 鳞癌较非鳞癌病理完全缓解率更高(39% vs 23%,P = .004),主要病理缓解率更高(66% vs 45%,P = .001)。
关键数值与推荐
- 临床II期与III期患者病理完全缓解率(P = .78)和主要病理缓解率(P = .26)相似。
- PD-L1≥50%患者病理完全缓解率37.5%,PD-L1<50%患者为27.2%(P = .082)。
临床怎么用
- 真实世界数据可用于II期和III期可切除非小细胞肺癌多学科治疗选择及共享决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the real clinical practice surgical outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre European cohort of patients. METHODS: Retrospective analysis on consecutive patients treated in 6 tertiary referral hospitals in Europe with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB non-small cell lung cancer (March 2023-December 2024). Surgical and pathological outcomes were assessed. RESULTS: A total of 340 patients started neoadjuvant treatment. Three hundred seventeen patients (93.2%) were able to proceed to surgery. Forty-seven percent of patients had surgery more than 6 weeks after completion of the last neoadjuvant cycle. Two hundred eight operations (66%) were started using a minimally invasive approach with a conversion rate of 18%. The most frequent resection was lobectomy in 86% of patients. Ninety-day postoperative mortality rate was 2.5%. The pathologic complete response occurred in 95 patients (30% of the surgical patients), major pathologic response in 167 patients (52.7% of the surgical patients). The incidence of pathologic complete response (P = .78) and major pathologic response (P = .26) were similar in patients with clinical stage II and III. Pathologic complete response rate was higher in patients with programmed death-ligand 1 (PD-L1) ≥ 50% compared to those with PD-L1 < 50% (37.5% vs 27.2%, P = .082). A higher pathologic complete response (39% vs 23%, P = .004) and major pathologic response (66% vs 45%, P = .001) were observed in squamous vs non-squamous histology tumours. CONCLUSIONS: The use of neoadjuvant nivolumab in association with platinum-based chemotherapy in the real clinical practice is safe and effective. Our real clinical practice data represent valuable information to be used during multidisciplinary treatment selection for clinical stage II and III resectable non-small cell lung cancer and shared decision-making.
引用
- Brunelli A, Mariolo A, Aigner C, et al. Surgical Results after Neoadjuvant Nivolumab and Platinum-based Chemotherapy for Resectable Lung Cancer. A Multicentre European Real Clinical Practice Analysis. Eur J Cardiothorac Surg. 2025. PMID: 41093743. doi:10.1093/ejcts/ezaf343
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。